Amgen Stock Drop Suit Booted By Supreme Court, But Not On Principle
This article was originally published in The Pink Sheet Daily
Former employees might not be able to sue Amgen regarding insider knowledge of Aranesp problems, but other firms could still face similar ERISA suits – and Amgen itself is still fighting litigation from disgruntled investors.
You may also be interested in...
Supreme Court rules 6-3 that plaintiffs do not need to prove that a company’s misrepresentations were material at the class certification stage; investors allege Amgen misrepresented the safety of Aranesp and Epogen.
The apparently first-ever FDA press release for an advertising warning letter underscores importance of opioid issues – and the agency’s changing approach to media relations in general. FDA objects to Alkermes journal ad that excludes risk information about its opioid dependence treatment drug.
Revised North American trade deal touted as enabling Congress to address crisis of high drug prices; requirement for 10 years biologic exclusivity is removed and language to allow incentives for generics added.